The "Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)" Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum
We have not yet decided what is the best way to share those details, but it could be, for example, in a government response to this consultation or when regulations are presented to the relevant national Parliament
Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors
On a cold day, if you, like me, enjoy smokingwhich I do, frankly
5 People with different types of MHCs are several times more likely to smoke than the general population, 6 , 7 and are responsible for a large proportion of overall tobacco consumption, 8 with one- third of cigarettes smoked by people with an MHC